Hi! I'm bonze blayk!

... Have you ever wondered what the DeathWorld is like?

This is but one of the many thrilling insights you may experience on an involuntary trip on mCPP!

A brief explanation of the "Executive Summary" below: mCPP is a potent anxiety-inducing drug (and a weak hallucinogen) that is the primary byproduct of Trazodone, a drug in common use as a sleeping aid. Prozac strongly interferes with the clearing of mCPP from the body... and moreover, some people have a poor ability to eliminate mCPP from their system to start with, due to their genetic endowment (including me!). Put all these together... and you may just get a train wreck. *I certainly did!*

I experienced the symptoms listed in the light blue and pink boxes...

A 3-Way Train Wreck on P450IID6: Kevin Eric Saunders, Jan-Feb 1997:

The elimination of mCPP, the principal metabolite of the "Sleeping Aid" Trazodone (Desyrel®), is potently inhibited by the "Antidepressant" Fluoxetine (Prozac®), its metabolite Norfluoxetine, and the "Sleeping Aid" Hydroxyzine (Vistaril®).



"It is well known that central serotonin agonists such as LSD and MCPP as well as dopamine agonists such as amphetamine and cocaine are capable of producing psychotic reaction (Huttunen 1995)."

"Clinical Psychopharmacology Seminar: Atypical Neuroleptics"
Paul Perry, Ph.D, BCPP, Brian C. Lund, Pharm.D.
University of Iowa Health Care. Peer Review Status: Internally Peer Reviewed.

"Even in low dosages, [antihistamines] are associated with impairment of daytime functioning. Furthermore, the anticholinergic effects of antihistamines (delirium, confusion, disorientation, etc.) may exacerbate problem behaviors."

"Appropriate Use of Psychotropic Drugs in Nursing Homes"
Tatyana Gurvich, Pharm.D., and Janet A. Cunningham, M.D., M.P.H.
American Family Physician, March 1, 2000

Table 1. Cytochrome P450 Enzymes and Drug-Drug Interactions

Function	IIC9	IIC19	IID6	Metab	IIIA4
Substrate	THC				(THC/CBD?)
Substrate			mCPP	<- 100% 3A4 <-	Trazodone
Substrate	Fluoxetine		Fluoxetine		
Substrate			Hydroxyzine		
Inhibitor		Fluoxetine	++Fluoxetine++	-> 2C9 ->	++Norfluoxetine++
Inhibitor			++Norfluoxetine++		
Inhibitor			+Hydroxyzine+		
Inhibitor	CBD?	CBD?			CBD
GENETICS	C 10	C 10	C 22		C 7
%PM (Poor Metabolizers)	Polymorphic 1-3% Cauc.	Polymorphic 3-5% Cauc. 15-20% Asian	Polymorphic 5-10% Cauc. (20% German)		

Table 2. in Vivo Study of the Effects of Fluoxetine on blood plasma levels of mCPP

Author	N	SSRI Treatment Dose (mg/day) x Duration (days)	Substrate Dosing	Substrate	(AUC2-AUC1)÷AUC1
Maes	11	20 x 28	mCPP	7 days	820% (270%/3,295%)‡

‡ 820% is based on all the data. If the two highest increases are excluded, the average was 270%. The two highest increases averaged 3,295%.

Adapted from: Preskorn SH. J Psychopharmacology. 1998;12:S89-S97.

(KES/bb, Rev. 2.1, 5/26/02)

A 3-Way Train Wreck on P450IID6 (PDF)

Side Effects Experienced on Prozac (JPG)

Side Effects Experienced on Trazodone (JPG)

KES/bb summary of abstracts on mCPP 5/22/00 (PDF - 23 pages)

KES/bb summary of abstracts on CYP2D6, Prozac, Trazodone, mCPP 5/24/00 (PDF - 21 pages)

"Is mCPP really an hallucinogen?"

"fuck yeah!"

"Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite),

and the hallucinogen trifluoromethylphenylpiperazine cross-react
with the EMIT-II ecstasy immunoassay in urine."

Logan BK, Costantino AG, Rieders EF, Sanders D.
Journal of Analytic Toxicology 2010 Nov;34(9):587-9.

"For sure?"

"Absolutely."

"Expert peer review on pre-review report: 1-(3-chlorophenyl)piperazine (mCPP)",

35th Expert Committee on Drug Dependence, Hammamet, Tunisia – June 4-8, 2012
World Health Organization.

"mCPP has psychostimulant, anxiety-provoking and hallucinogenic effects. The effects are noted 45-90 minutes after oral administration and include euphoria, illusions (colour enhancement), circum-oral paraesthesia, and in higher doses overt hallucinosis equivalent to primary hallucinogens such as lysergic acid diethylamide (LSD)."

"Do *you* have a metabolic defect caused by GENETICS?"

"FUCK YEAH!"



7/28/2010 3:57 PM FROM: Fax Genelex Corporation TO: 1-607-216-0902 PAGE: 003 OF 011

genelex
Science that benefits humanity

DNA DRUG SENSITIVITY TEST (DST) RESULTS
Cytochrome P450 2D6 Test

Genelex Laboratory # **CRM 16424** Report Date: July 27, 2010



Patient Name: Kevin E. Saunders Collection Date: 7/16/2010

Date of Birth: 5/1/1956 Sample Type: Blood Receipt Date: 7/19/2010

Cytochrome P450 2D6 Genotype (Phenotype) Interpretation: **DST- CYP 2D6 *1 / *4 (Intermediate Metabolizer)**

Laboratory Director: Teresa H. Aulinskas, Ph.D.

Laboratory Test Interpretive Comments:

Normal metabolizers represent the norm for metabolic capacity. In general normal metabolizers can be administered drugs which are substrates of the CYP2D6 enzyme following standard dosing practices. Genotypes consistent with the normal metabolizer phenotype include two active CYP2D6 alleles or one active and one partially active CYP2D6 allele. Increased caution may be appropriate for individuals having one partially active allele.

Intermediate metabolizers may require lower than average drug dose for optimal therapeutic response to medications with the exception of prodrugs. For the majority of drugs consider decreased dosage. For prodrugs, like tamoxifen, that require activation by CYP2D6, an alternative treatment or increased dose should be considered. Genotypes consistent with the intermediate metabolizer phenotype are those with one active and one inactive CYP2D6 allele, one inactive and one partially active CYP2D6 allele, or two partially active CYP2D6 alleles.

Poor metabolizers are at increased risk of drug-induced side effects due to diminished drug elimination or for prodrugs, like tamoxifen, lack of therapeutic effect resulting from failure to generate the active form of the drug. Alternative treatment should be considered. Genotypes consistent with the poor metabolizer phenotype are those with no active CYP2D6 alleles.

Ultra metabolizers exhibit higher than average rates of metabolism. Ultra metabolizers are at increased risk of therapeutic failure due to increased drug elimination and thus may require an increased dose of drugs that are inactivated by CYP2D6. For prodrugs, ultra metabolizers may also be at increased risk of drug-induced side effects due to increased exposure to active drug metabolites, in which case they may require lower than average doses. Genotypes consistent with ultra metabolizer phenotype include three or more active CYP2D6 alleles due to duplication of an active allele.

Co-administration of other drugs. Genotype results should be interpreted in context of the individual clinical situation including co-administration of other drugs, hepatic and renal function. In all cases monitor for co-administration of CYP2D6 inhibitors which may convert patients to poor metabolizer status. Potential adverse outcomes included overdose toxicity or treatment failure particularly for prodrugs. For more information see GeneMedRx drug-drug and drug-gene interaction software and Cytochrome P450 Metabolism Inhibitor/Inducer Tables. Access GeneMedRx via the patient access code provided at www.GeneMedRx.com/DNAlogin.

DNA Drug Sensitivity Test (DST) Cytochrome P450 CYP2D6 alleles tested:

Active alleles: CYP2D6 *1 or *2
Partially active alleles: CYP2D6 *9 or *10 or *17 or *41
Inactive alleles: CYP2D6 *3 or *4 or *5 (deletion) or *6 or *7 or *8 or *11 or *12 or *14 or *15
Gene Duplication: CYP2D6 *1 or *2 or *4 or *10 or *41
Analytical specificity and sensitivity for detection of these mutations are 99%. Other known variants not listed are not detected (< 5% of the population for Caucasians).
Note: This is a list of all tested markers and is no indication of your genetic profile. Your genotype is in the box above.

For more detailed information visit our website at www.healthandDNA.com **Page 1 of 2**

Genelex Corporation • 3000 First Avenue, Suite One, Seattle, Washington 98121, 1-800 523-6487 www.HEALTHandDNA.com,
Accredited DNA Testing World Leader Since 1987

Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone.
R. E. Kast. World Journal of Biological Psychiatry 2009;10(4 Pt 2):682-5.

"This commentary argues that the documented potential for harm and multiple risks of m-CPP outweigh potential benefits of trazodone..."

Are we done with trazodone? The potential for damage by m-CPP - a metabolite of trazodone.
R. E. Kast. Acta Neuropsychiatrica Volume 19, Issue 3, pages 220-221, June 2007.

Folks with defective CYP2D6*4 alleles (such as myself!) love to smoke cannabis...
Genetic Polymorphism Of Cytochrome P450 2D6 * 4 In Cannabis Smokers
M. A. Sohayla, Z. E. Ayman & E. Ayman. The Internet Journal of Toxicology. 2008 Vol 5 No 1.
Why?

"Murple" relates a very unpleasant experience with 50mg of Trazodone, courtesy of the Erowid Vaults: "I can't believe that something which turns to mCPP in the body is sold as an unscheduled prescription drug!!!" (Erowid Added: Dec 29, 2003)

I took 275mg of Trazodone over 7 days, on top of 20mg/day Prozac and a defective CYP2D6/P450IID6 metabolism! Yippee!

And it was my first exposure ever to a synthetic hallucinogen...

Consequences... and Truth:

My Medwatch report to the FDA, submitted on 12/30/2002.

---

bonze blayk - guinea

Rush - Driven

A timely release by RUSH was a consolation

… and I'd never seen this video until sometime around 2010!
Yet - how apropos the whole affair!
LAUGHING OUT LOUD

DRIVEN
Lee, Lifeson, & Peart

Driven up and down in circles
Skidding down a road of black ice
Staring in and out storm windows
Driven to a fool's paradise

BUT IT'S MY TURN TO DRIVE

Driven to the margin of error
Driven to the edge of control
Driven to the margin of terror
Driven to the edge of a deep, dark hole

Driven day and night in circles
Spinning like a whirlwind of leaves
Stealing in and out back alleys
Driven to another den of thieves

BUT IT'S MY TURN TO DRIVE

Driven in -- Driven to the edge
Driven out -- On the thin end of the wedge
Driven off -- By things I've never seen
Driven on -- By the road to somewhere I've never been

IT'S MY TURN TO DRIVE

The road unwinds towards me
What was there is gone
The road unwinds before me
And I go riding on

My New Year's Resolution for 2011...
I will see a warning label placed on Trazodone.

- Bonze Anne Rose Blayk

(F/K/A "Kevin Eric Saunders a/k/a bonze blayk")

bonze blayk's Anomaly - NO ACTION - HQ

UP

HOME

Updated 11/6/10, 1/7/11, 2/1/11, 6/30/11, 10/2/11, 3/20/12, 11/26/12, 4/30/13